Perioperative Glutamine Supplementation and Cachexia

NCT ID: NCT05023499

Last Updated: 2021-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

550 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2021-08-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background Sarcopenia is characterized by the degenerative loss of skeletal muscle and is associated with increased adverse surgical outcomes. Glutamine is considered as an immune-modulating formula, which may stimulate protein synthesis in the skeletal muscle but also inhibited protein-degradation. In this study, the investigators calculate the area and volume psoas major muscle (PMMA; PMMV) of the third lumbar vertebral body as the reference of skeletal muscle. The aim of this study is to investigate whether perioperative glutamine supplementation restores atrophy of psoas muscle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 550 gastric adenocarcinoma (GA) patients undergoing gastrectomy were enrolled for the study. Computed tomography was used to assess the short axis of the psoas muscle, and the change was calculated between preoperative day and three months after gastrectomy. Perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use. A linear regression model was performed to predict this association by adjusting clinic-demographics and nutritional calories.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glutamine; Metabolic Disorder Cachexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With glutamine supplementation

perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

SYMPT-X Glutamine, Oral Powder for Reconstitution

Intervention Type DRUG

erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

Without glutamine supplementation

no glutamine use

SYMPT-X Glutamine, Oral Powder for Reconstitution

Intervention Type DRUG

erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SYMPT-X Glutamine, Oral Powder for Reconstitution

erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SYMPT-X

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* gastric cancer patients undergoing gastrectomy

Exclusion Criteria

* hepatic or renal failures
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201909033RIND

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Glutamine on Gastric Emptying
NCT00943020 COMPLETED PHASE4
Postoperative Muscle Loss After Gastrectomy
NCT07331038 NOT_YET_RECRUITING
Postoperative Electrical Muscle Stimulation Two
NCT06964438 NOT_YET_RECRUITING NA